I think so. New product development pipeline looks very impressive. CSL112 to treat with HDL increases for heart attack victims looks very advance in its process to get approval. CSL deserves higher PE due to high R&D expense of $1.2B will provide future results like CSL112. The other way to look at is if it reduces R&D by 40%, PE will be low twenties on future 3 year earnings .
- Forums
- ASX - By Stock
- CSL
- Fair Value
Fair Value, page-118
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$309.72 |
Change
0.430(0.14%) |
Mkt cap ! $149.6B |
Open | High | Low | Value | Volume |
$310.10 | $311.54 | $308.61 | $295.6M | 953.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 14819 | $309.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$310.00 | 36 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 905 | 309.570 |
1 | 73 | 309.480 |
2 | 4623 | 309.400 |
1 | 858 | 309.240 |
1 | 731 | 309.220 |
Price($) | Vol. | No. |
---|---|---|
310.000 | 36 | 1 |
310.170 | 482 | 1 |
310.500 | 64 | 1 |
310.560 | 500 | 1 |
310.630 | 716 | 1 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online